Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar mmacioci (63.74) Submitted: 9/5/2010 7:10:30 PM : Outperform Start Price: $4.38 PGNX Score: +73.23

John Paul Pick ask Ray

Featured Broker Partners


Advertisement